Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipragliflozin add-on to Sitagliptin in Japanese T2DM
NCT02564211Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of ipragliflozin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Who Experienced at Least 1 Adverse Event (AE) at 54 weeks and Percentage of Participants Who Had Study Drug Discontinued Due to an AE at 52 weeks. Started Oct 2015; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02564211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564211.